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Abstract
Background: The fragile X mouse model shows an increase in seizure susceptibility, indicating an involvement of
the GABAergic system via an alteration in cellular excitability. In the brain, we have previously described a
reduction in GABAA receptor expression as a likely basis for this susceptibility. In the brains of fragile X mice, this
reduction in receptor expression culminates with a concomitant increase in the expression of glutamic acid
decarboxylase (GAD), the enzyme responsible for GABA synthesis. Further, voltage-sensitive calcium channel
expression is reduced in the pancreas of the fragile X mouse. Since there are considerable similarities in the
GABAergic system in the brain and pancreas, we evaluated the protective role of taurine in pancreatic islet
development in both wild type (WT) and fragile X mice (KO).
Methods: One-month-old FVB/NJ males or age-matched fmr1-knockout (KO) mice were supplemented with
taurine in drinking water (0.05% w/v) for four weeks. Age-matched controls were fed water only for the same
duration. At four weeks, mice were sacrificed and pancreases processed for histology and immunohistochemical
studies on changes of insulin, glucagon and somatostatin expression. Additional mice were subjected to a glucose
tolerance test.
Results: Taurine treatment resulted in a significant increase in the number and size of islets. WT taurine-fed mice,
slightly hypoglycemic prior to glucose injection, showed significantly reduced plasma glucose at 30 min post-
injection when compared to control mice. KO mice had normal baseline plasma glucose concentration; however,
following glucose injection they had higher plasma glucose levels at 30 min when compared to controls.
Supplementation of taurine to KO mice resulted in reduced baseline levels of plasma glucose. After glucose
injection, the taurine-fed KO mice had reduced plasma glucose at 30 min compared to KO. Concomitant with the
increased islets size and glucose tolerance observed in taurine-fed mice there was an increase in insulin, glucagon
and somatostatin immunoreactivity in the islets of WT mice. In the KO mice however, insulin levels were not
affected whereas glucagon and somatostatin levels were reduced. Exocytosis of these hormones is calcium-
dependent, therefore any exacerbation of calcium homeostasis could affect hormone release. We found the
expression of the voltage sensitive calcium channels (VSCC) is drastically reduced in the pancreas of fragile X mice.
Conclusions: During early development, the VSCC play an important role in calcium-dependent gene expression.
Since these channels are also involved in depolarization and calcium-mediated vesicular release of
neurotransmitters and pancreatic hormones, alterations in the expression of VSCC not only will affect calcium-
mediated gene expression but also hormonal and neurotransmitter release creating therefore a neuroendocrine
perturbation in the fragile X that may potentially affect other organ systems. We find that in the fragile X mouse,
taurine treatment may partially restore functionality of the neuro-endocrine pancreas.
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The fragile X syndrome includes hyperarousal, hyper-
sensitivity to sensory stimuli and an increased preva-
lence of seizures [1,2]. The mouse model for this
disorder [3,4] is a knockout of the fmr1 gene (fragile X
mental retardation 1 gene) which has a reduction in the
expression of the fragile X mental retardation protein
(FMRP). This model has increased seizure susceptibility
[5-7] which may be a direct parallel to elements of the
syndrome that suggest reduced inhibition/increased
excitability. Our investigations of the molecular basis of
increased seizure susceptibility in the fragile X mouse
indicate a reduction in GABAA receptor expression [8].
Since these receptors play a major role in inhibition,
their reduction helps explain the increased seizure sus-
ceptibility in this mouse model for fragile X and suggest
that the GABAergic system may be affected in the fra-
gile X syndrome.
We have previously described an increased expression
of glutamic acid decarboxylase (GAD), the enzyme
responsible for the synthesis of GABA, the neurotrans-
mitter agonist for GABAA receptors. This increase is
likely a response of the brain to reduced inhibition - a
response that has been observed in other models of
elevated excitability [9]. The excitability of neuronal cir-
cuits is kept within a normal range through feed-for-
ward and -back inhibition, mediated by inhibitory
interneurons. These neurons continuously adjust their
inhibitory output to match the level of excitatory input.
Thus, when there is reduced inhibition of postsynaptic
neurons, feedback from these neurons causes the presy-
naptic neurons to increase their inhibitory output. In
the example of fragile X mouse brain, reduced GABAA
receptor expression on postsynaptic membranes would
induce an increase in GAD expression, thus increasing
the bioavailability of GABA in presynaptic terminals.
Therefore, increased GAD may represent a secondary
response to the direct effects of FMRP depletion.
We have previously demonstrated [10-12] that mice
chronically supplemented with taurine in their drinking
water showed biochemical changes in the GABAergic
system similar to those observed in fragile X mouse,
including a reduced GABAA receptor, increased GAD
expression and a lower threshold for seizure induction.
Taurine (2-aminoethanesulfonic acid) is a sulfur-con-
taining amino acid. It is one of the most abundant free
amino acids in many excitable tissues, including the
brain, skeletal and cardiac muscles. Physiological
actions of taurine are widespread and include bile acid
conjugation, detoxification, membrane stabilization,
osmoregulation, neurotransmission and modulation of
cellular calcium levels [13-17]. Furthermore, taurine
plays an important role in modulating glutamate and
GABA neurotransmission [18-20]. We have previously
shown that taurine prevents excitotoxicity in vitro pri-
marily through modulation of intracellular calcium
homeostasis [18].
Outside of the central nervous system, taurine also is
essential during developmental processes. Taurine is
added to milk formula and in a solution for parenteral
nutrition of premature babies to prevent retinal degen-
eration and cholestasis [21,22]. Taurine is found at high
concentrations in pancreatic islets [21] and is able to
prevent pancreatic alterations induced by gestational
malnutrition especially low-protein diet [23-26]. In addi-
tion, taurine administration during gestation delays the
mean onset time of diabetes in non-obese diabetic
(NOD) mice [27]. Taurine supplementation to dams fed
a normal diet produces weak glucose intolerance and
decreases islet sensitivity to cytokines in offspring [26].
Moreover, taurine participates in glucose metabolism in
adults [28-30].
Previous reports show that the islets from taurine-
treated mice had almost double the number of cells
positive for proliferating cell nuclear antigen (PCNA).
This increased proliferation was accompanied by a
reduction in the incidence of apoptosis in islet cells, and
also a significant increase in the number of islet cells
immunopositive for IGF-II [27]. Peak of islet cell apop-
tosis is maximal in the rat pancreas 14 days after birth
and is temporally associated with a fall in the islet cell
expression of IGF-II [31]. IGF-II functions as an islet
survival factor in vitro. The induction of islet cell apop-
tosis in vivo may involve an increased expression of
inducible nitric oxide synthase (iNOS) within b-cells.
Interestingly, taurine is a potent inhibitor of iNOS [32].
Methods
Animals: All mice used in this study were two-month-
old FVB/NJ males. For taurine-fed mice, taurine was
dissolved in water at 0.05%, and this solution was made
available to the mice in place of drinking water for
4 weeks beginning at 4 weeks of age. All mice were
housed in groups of three in a pathogen-free room
maintained on a 12-hr light/dark cycle and given food
and water ad libitum. All procedures were approved by
the Institutional Animal Care and Use Committee of
the College of Staten Island/CUNY, and were in confor-
mity with National Institutes of Health Guidelines. The
number of mice sufficient to provide statistically reliable
results was used in these studies.
Quantification of size and number of pancreatic islets:
Two-month-old mice were perfused with 4% parafor-
maldehyde and pancreases were isolated attached to the
pyloric region of the stomach and the duodenum.
The initial part of the duodenum served to orient the
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Page 2 of 8pancreas for the sectional plane. Tissue was cryopro-
tected with 30% sucrose and cryosectioned at a thick-
ness of 30 µm. Sections were stained with hematoxylin
and eosin. Contiguous sections were stained with propi-
dium iodide to visualize condensed chromatin as an
indication of apoptotic cell death. Microscopy was per-
formed independently by three laboratory assistants
unaware of the treatment conditions.
Immunohistochemistry: Cryosections were made as
described above and placed onto gelatin-subbed slides.
Non-specific binding sites were blocked using 4%
bovine serum albumin (BSA), 2% normal goat serum
(NGS), and 0.05% Triton X-100 in 0.01M phosphate-
buffered saline (pH 7.4). Following the blocking step,
the slides were rinsed in an antibody dilution cocktail
(ABD) consisting of 2% BSA and 1% NGS in 0.01M
PBS. Primary antibodies (Chemicon International,
Temecula CA) employed were directed against insulin
(mouse host), glucagon (rabbit host), or somatostatin
(rabbit host) and diluted 1:500 in ABD. For these stu-
dies, the mouse anti-insulin was paired with either rab-
bit anti-glucagon or rabbit anti-somatostatin. The
primary antibodies were incubated overnight at 4
oC
and then unbound antibodies rinsed with ABD. Sec-
ondary antibodies were all raised in goat and directed
against appropriate primary antibody type. The
anti-mouse IgG was conjugated to Alexa Fluor 488
(Invitrogen/Molecular probes, Carlsbad CA) and the
anti-rabbit IgG was conjugated to Cy5 (Jackson Immu-
nological, West Grove PA). Images were obtained by
confocal microscopy (Leica SP2 AOBS). To determine
relative changes in protein expression, the gain and
offset was identical for all comparisons. Once the
images were obtained, relative fluorescence levels were
identified for eight islets per treatment, with 30 regions
of interest of identical dimensions set for each islet.
Changes in expression were also confirmed statistically
using the Imaris x 64 software (Bitplane).
Intraperitoneal Glucose Tolerance Test: Mice from
both groups were fasted overnight (12h) and then
injected intraperitoneally with 0.02 ml/g of body weight
D-glucose (7.5 % stock soluti o ni ns a l i n e ) .B l o o ds a m -
ples were taken by tail venesection at 0 min (just before
glucose injection) and at 30min intervals after the glu-
cose load. Glucose was measured with Ascensia Breeze
portable glucose meter (Bayer, Germany). Mice were
given only water during the test.
Results
Taurine supplementation increases the size and number
of the islets of Langerhans
Histological examination of the pancreas revealed that
the KO mice had a significant reduction in the number
of islets of Langerhans when compared to controls
(Fig. 1; p<0.05). Furthermore, there were no noticeable
histological abnormalities in the endocrine or exocrine
parts of the pancreas. Surprisingly, supplementation of
taurine in the drinking water resulted in a drastic and
significant increase in the number of islets per section
in both WT and KO mice (Fig. 1; p<0.001 for WT,
p<0.01 for KO). Previously, it has been reported [27]
that the islets from taurine treated mice had almost
double the number of cells immunopositive for prolifer-
ating cell nuclear antigen (PCNA). This increase prolif-
eration was accompanied by a reduction in the
incidence of apoptosis in islet cells, and also a significant
increase in the number of islet cells immunopositive for
IGF-II. These data demonstrate that the endocrine pan-
creas undergoes significant modification during neonatal
life, and that proliferation and apoptosis are integral
mechanisms in this remodeling.
Taurine-fed mice show hyperinsulinemia and glucose
tolerance
To determine the functional significance of increased
islets size and number in the pancreas of taurine-fed
mice, we tested the tolerance of mice to glucose injec-
tion as an indicator of the pancreas efficiency to regulate
plasma glucose homeostasis. As expected, control mice
showed a drastic increase in plasma glucose concentra-
tion 30 min after challenge with a gradual decrease
through 120 min. By the end of the experiment, mice
were slightly hypoglycemic relative to baseline (Fig. 2).
In contrast, taurine-fed control mice showed a signifi-
cant tolerance to glucose injection. Baseline plasma glu-
cose levels indicated that these mice were slightly, but
not significantly, hypoglycemic compared to controls.
However, the response to glucose injection was drasti-
cally reduced (p < 0.001) at 30 min compared to con-
trols. At 60 min following the challenge, the plasma
glucose level in the taurine-fed mice rose slightly but
was still significantly reduced than controls. Not until at
120 min post-challenge that the plasma glucose levels
were similar in both groups. KO mice had similar base-
line plasma glucose levels as WT. However, 30 min post
glucose injection, glucose plasma levels were higher
than those of WT. At 60 min KO plasma glucose levels
were the same as WT, but two hours post injection WT
plasma glucose levels continue to decline whereas the
KO plasma glucose levels remained significantly higher
than WT. Interestingly, when KO mice were fed taurine
f o rf o u rw e e k sp r i o rt ot h eg l u c o s et e s tt h e ya l m o s t
reacted as WT controls. Taurine supplementation
induced hypoglycemia in KO mice at baseline, glucose
levels were lower 30 min post injection and drastically
reduced after 2 h when compared to non-taurine-fed
KO mice (Fig.2).
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Page 3 of 8Figure 1 Taurine induces an increase in the number of islets in the pancreas. A l lm i c ew e r e2m o n t h so l d .T a u r i n e( 0 . 0 5 % )w a s
supplemented in the drinking water. WT, n=3; KO, n=4; WT-Tau, n=3; KO-Tau, n=3. Pancreata were cryosectioned (30 µm) and stained with
hematoxylin and Eosin. Each pancreas yielded approximately 150 sections. All pancreata were cut in the longitudinal plane. WT-tau had the
largest number of islets per section. KO had significantly less islets than controls and treatment with taurine caused a significant increase in the
number of islets. Insert shows an islet from control (left) and taurine-fed WT mouse stained with propidium iodide
Figure 2 Effect of taurine supplementation on glucose homeostasis Intraperitoneal glucose tolerance test on overnight fasted mice. All
mice were 2 months old. Taurine (0.05%) was supplemented in the drinking water. WT, n=9; KO, n=12; WT-Tau, n=10; KO-Tau, n=12.Values are
expressed as means ± S.E.M obtained from three experiments.
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function of the pancreas
Since plasma glucose levels are inversely correlated to
the plasma insulin levels, which in turn are determined
by insulin levels present in and released from the islets.
Here we sought to determined a possible functional par-
allel between the enlargement of islet size in response to
taurine supplementation, the number of islets, the resis-
tance to glucose-induced hyperglycemia and the levels
of the three main pancreatic peptides: insulin, glucagon
and somatostatin. We found that the levels of these
markers were significantly (p<0.01) increased in
response to taurine supplementation in the drinking
water. In these mice, insulin levels were increased by
50%, glucagon levels were increased by 100% and soma-
tostatin levels by 300% (Fig. 3 A-E ). The increase in
insulin level is consistent with the diminished peak of
plasma glucose levels at 30 and 60 min.
Altered pancreatic hormones in fragile X mice
In the intraperitoneal glucose tolerance test, Fragile X
mice showed elevated glucose levels at 30 min when
compared to WT controls (Fig. 2), suggestive of poten-
tially altered pancreatic hormonal levels. Therefore, we
measured the levels of the main pancreatic hormones by
quantifying the intensity of immunoreactivity of these
hormones. Interestingly we found that the levels of insu-
lin immunoreactivity were not affected in fragile X mice
pancreas whereas glucagon and somatostatin were
reduced (Fig. 4).
Plasma glucose level is mainly controlled by insulin
and glucagon. These two hormones are antagonistic to
each other and their secretion is partially controlled by
somatostatin. Reduced glucagon and somatostatin
expression in the fragile X pancreas could be responsible
for the altered response to the glucose tolerance test
observed in the fragile X mice.
Figure 3 Decreased hormonal expression in the fragile X pancreas Effect of taurine supplementation on insulin, glucagon and somatostatin
expression in pancreatic islets. A and B Representative confocal images showing insulin (Green) and glucagon (Red) immunoreactivity in
pancreatic islets from control and taurine-fed mouse, respectively. C and D somatostatin immunoreactivity in the islets from a control and a
taurine-fed mouse, respectively. E. Immunoreactivity intensity ratio of taurine-fed over controls.
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fragile X mice
In neurons, the main route for calcium entry is the
activation of NMDA and VSCC. In the pancreas how-
ever, calcium enters only through VSCC expressed on
the islet cells. These channels are activated through
depolarization mediated by the electrogenic transport
of glucose that is coupled with sodium. Thus, activa-
tion of the VSCC on the b-cells causes the co-release
of GABA and insulin. GABA inhibits glucagon release
while insulin lowers plasma glucose concentration. We
found that fragile X mice have reduced expression of
the VSCC in the islets of Langerhans (Fig. 5). Such a
reduction in the expression of these channels would
result in reduced calcium influx and reduced intracel-
lular calcium necessary for vesicular release of pan-
creatic hormones, thus leading to the altered handling
of glucose loads.
Discussion
Histological examination of the pancreas revealed that
taurine-fed mice had a significant increase in the size of
islets of Langerhans when compared to controls (Fig. 1).
There were no noticeable histological abnormalities in
the endocrine or exocrine parts of the pancreas. Surpris-
ingly, supplementation of taurine in the drinking water
resulted in a drastic and significant increase in the num-
ber of islets per section (Fig.1). KO mice had fewer islets
than WT mice and these islets were relatively smaller.
Addition of taurine to the drinking water of KO mice
resulted in a drastic increase in the number of islets.
However, supplementation of taurine to KO mice did
not induce the same level of changes observed in the
WT mice. This could be due to the differential sensitiv-
ity to taurine between WT and KO mice or to efficiency
of downstream signaling mechanisms activated by taur-
ine. As PCNA and IGF-II levels increase and apoptosis
decreases in the islets of taurine-fed mice, the assump-
tion that taurine may prevent apoptotic remodeling in
the developing pancreas has been proposed [27,31]. We
provide evidence here that the consequence of apoptosis
inhibition by taurine was an increase in the size and
perhaps the number of islets. Scaglia et al., [33] have
shown increased replication and decreased incidence of
apoptosis in b-cells in the presence of IGF-II. Consistent
with these observations, we found that supplementation
of taurine in the drinking water for 4 weeks resulted in
a significant increase in the number and size of islets
(Fig. 1). Functionally, this may also be coupled with
Figure 4 Decreased hormonal expression in the fragile X
pancreas To determine relative changes in hormonal expression,
the gain and offset was identical for WT and KO comparisons. Once
the images were obtained, relative fluorescence levels were
identified for eight islets per genotype, with 30 regions of interest
of identical dimensions set for each islet.
Figure 5 Decreased expression of the VSCC in the fragile X pancreas Representative confocal images showing VSCC immuno-reactivity in
pancreatic islets from WT and Fmrp1-KO mice, respectively. Sections were counterstained with the nuclear stain DAPI.
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somatostatin levels in the islets.
Concomitant with these histological observations, we
found that the immunoreactivity of the main pancreatic
markers was significantly elevated following taurine sup-
plementation (Fig. 3). Such an increase in pancreatic
hormonal levels offered tight regulation of plasma glu-
cose levels when these mice were challenged with ele-
vated glucose levels during a glucose tolerance test (Fig.
2). The increased levels of expression of these markers
that we report here were from comparison of regions of
interest in the islets, and not from total number of cells
in the pancreas producing the markers. We therefore
hypothesize that the taurine not only lead to more islets
in the pancreas but subsequently to increases in the
expression of these peptides within the islet cells.
We have shown previously [34] that taurine supple-
m e n t a t i o nt om i c er e s u l t e di na ni n c r e a s eo fb r a i n
somatostatin levels. Here we showed that the effects of
taurine on somatostatin expression are not limited to
the brain but include the pancreas and potentially other
somatostatin-expressing organs. The observed effects of
taurine on the upregulation of somatostatin expression
are not well understood and could be mediated at the
transcriptional level.
The other important finding of this study is the
reduced expression of VSCC. Such a drastic reduction
would affect hormonal release and thus plasma glucose
homeostasis.
Conclusions
Fragile X mice have reduced expression of the VSCC
(pancreas and brain, not shown here). This could poten-
tially explain the altered plasma glucose homeostasis and
altered neuronal excitability in the fragile X brain. We
have, as well as others, previously shown that the func-
tion of the GABAergic system is altered in the Fmrp1-
KO mice. Here, we show further that the alterations in
the GABAergic system coupled with reduced expression
of the VSCC may be responsible for the altered glucose
homeostasis observed in the fragile X mice.
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